Because we observed elevated markers of oxidative damage both in the circulation and in the liver, we investigated further whether oxidative dysregulation could contribute to NAFLD and the later development of insulin resistance; this confirmed an impaired hepatic antioxidant capacity through reduced GPx1 expression. The gene discussed is GPX1; the disease is metabolic dysfunction-associated steatotic liver disease.